Towards a new therapeutic target: Helicobacter pylori flavodoxin

Biophysical Chemistry

Volumn 115, Issue 2-3 SPEC. ISS., 2005, Pages 267-276

  Cremades, Nunilo ^a,b   Bueno, Marta ^a,b   Toja, Miguel ^c   Sancho, Javier ^a,b  

^a Biocomputation Complex Syst P   (Spain)

^b UNIVERSITY OF ZARAGOZA   (Spain)

^c Operon SA Cuarte de Huerva   (Spain)

Author keywords

Drug design; Flavodoxin; Helicobacter pylori; Protein cavity; Protein stability; Small molecule binding

Indexed keywords

ELECTRON TRANSFERRING FLAVOPROTEIN; FLAVINE MONONUCLEOTIDE;

BACTERIAL GENE; BACTERIAL GENOME; CONFERENCE PAPER; CONTROLLED STUDY; ESCHERICHIA COLI; HELICOBACTER PYLORI; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PURIFICATION;

EID: 14744268574     PISSN: 03014622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpc.2004.12.045     Document Type: Conference Paper

References (53)

1. J.R. Warren, and B.J. Marshall Unidentified curved bacilli on gastric epithelium in active chronic gastritis Lancet 1 1983 1273 1275
2. R.A. Feldman M. Achtman S. Suerbaum Helicobacter pylori: molecular and cellular biology. Epidemiologic observations and open questions about disease and infection caused by Helicobacter pylori 2001 Horizon Scientific Norfolk
3. J. Parsonnet The incidence of Helicobacter pylori infection Aliment. Pharmacol. Ther. 9 suppl. 2 1995 45 51
4. M.J. Blaser Hypotheses on the patogenesis and natural history of Helicobacter pylori-induced inflammation Gastroenerology 102 1992 720 727
5. J. Parsonnet, G.D. Friedman, D.P. Vandersteen, Y. Chang, J.H. Vogelman, N. Orentreich, and R.K. Sibley Helicobacter pylori infection and the risk of gastric carcinoma N. Engl. J. Med. 325 1999 1127 1131
6. A.C. Wotherspoon, C. Doglioni, T.C. Diss, L. Pan, A. Moschini, M. de Boni, and P.G. Isaacson Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori Lancet 342 1993 575 577
7. D.E. Taylor, M. Eaton, N. Chang, and S.M. Salama Construction of a Helicobacter pylori genome map and demonstration of diversity at the genome level J. Bacteriol. 174 1992 6800 6806
8. Y. Glupczynski, and A. Burette Drug therapy for Helicobacter pylori infection: problems and pitfalls Am. J. Gastroenterol. 85 1990 1545 1551
9. K. Seppala, and H. Nuutinen New options in eradication of Helicobacter pylori Ann. Med. 27 1995 601 604
10. S. Mendonca, C.C. Ecclissato, M.S. Sartori, A.P. Godoy, R.A. Guersoni, M. Deguer, and J. Pedrazzoli Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin, tetracycline, and furazolidone in Brazil Gastroenterology 118 Part 2 Suppl. 2 2000 5822
11. J.J. Kim, R. Reddy, S.G. Reddy, F.A. El-Zaatari, M.S. Osato, J.G. Kim, D.Y. Graham, and D.H. Kwon Increasing Helicobacter pylori resistance to metronidazole, clarithromycin and tetracycline Gastroenterology 118 Part 1 Suppl. 2 2000 2671
12. R.J. Adamek, S. Suerbaum, B. Pfaffenbach, and W. Opferkuch Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin-influence on treatment outcome Am. J. Gastroenterol. 93 1998 386 389
13. F. Megraud Helicobacter pylori resistance to antibiotics Presse Med. 26 1997 1775 1780
14. F. Megraud Resistance of Helicobacter pylori to antibiotics: the main limitation of current proton-pump inhibitor triple therapy Eur. J. Gastroen. Hepatol. 11 Suppl. 2 1999 S35 S37
15. F. Megraud, J. Laurent, J.F. Flejou, A. Caekaert, and P. Barthelemy Helicobacter pylori resistance to antimicrobial agents after treatment failure with omeprazole triple therapy Gastroenterology 116 Part 2 1999 G0519
16. K. Murakami, T. Fujioka, T. Kubota, R. Sato, M. Kodama, M. Kimoto, and M. Nasu Prevalence of acquired Helicobacter pylori resistance to clarithromycin and combinations of eradication regimens Gastroenterology 116 Part 2 1999 G1138
17. M.F.T. Rupnow, R.D. Shachter, D.K. Owens, and J. Parsonnet Quantifying the population impact of a prophylactic Helicobacter pylori vaccine Vaccine 20 2001 879 885
18. J.S. Kim, J.H. Chang, S.I. Chung, and J.S. Yum Importance of the host genetic background on immune responses to Helicobacter pylori infection and therapeutic vaccine efficacy FEMS Immunol. Med. Microbiol. 31 2001 41 46
19. C. Hatzifoti Helicobacter pylori vaccine strategies-triggering a gut reaction Trends Immunol. 22 2001 225
20. P. Legrain, and D. Strosberg Protein interaction domain mapping for the selection of validated targets and lead compounds in the anti-infectious area Curr. Pharm. Des. 8 2002 1189 1198
21. R.A. Alm, L.S. Ling, D.T. Moir, B.L. King, E.D. Brown, P.C. Doig, D.R. Smith, B. Noonan, B.C. Guild, B.L. deJonge, G. Carmel, P.J. Tummino, A. Caruso, M. Uria-Nickelsen, D.M. Mills, C. Ives, R. Gibson, D. Merberg, S.D. Mills, Q. Jiang, D.E. Taylor, G.F. Vovis, and T.J. Trust Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori Nature 397 1999 176 180
22. N.J. Hughes, C.L. Clayton, P.A. Chalk, and D.J. Kelly Helicobacter pylori porCDAB and oorDABC genes encode distinct pyruvate:flavodoxin and 2-oxoglutarate: acceptor oxidoreductases which mediate electron transport to NADP J. Bacteriol. 180 1998 1119 1128
23. P. Kaihovaara, J. Hook-Nikanne, M. Uusi-Oukari, T.U. Kosunen, and M. Salaspuro Flavodoxin-dependent pyruvate oxidation, acetate production and metronidazole reduction by Helicobacter pylori J. Antimicrob. Chemother. 41 1998 171 177
24. J. Freigang, K. Diederichs, K.P. Schafer, W. Welte, and R. Paul Crystal structure of oxidized flavodoxin, an essential protein in Helicobacter pylori Protein Sci. 11 2002 253 261
25. C. Osborne, L.M. Chen, and R.G. Matthews Isolation, cloning, mapping, and nucleotide sequencing of the gene encoding flavodoxin in Escherichia coli J. Bacteriol. 173 1991 1729 1737
26. S. Wakabayashi, T. Kimura, K. Fukuyama, H. Matsubara, and L.J. Rogers The amino acid sequence of a flavodoxin from the eukaryotic red alga Chondrus crispus Biochem. J. 263 1989 981 984
27. E.E. Scott, Y.A. He, M.R. Wester, M.A. White, C.C. Chin, J.R. Halpert, E.F. Johnson, and C.D. Stout An open conformation of mammalian cytochrome P450 2B4 at 1.6-A resolution Proc. Natl. Acad. Sci. U. S. A. 100 2003 13196 13201
28. C.S. Chang, L.T. Chen, J.C. Yang, J.T. Lin, K.C. Chang, and J.T. Wang Isolation of a Helicobacter pylori protein, FldA, associated with mucosa-associated lymphoid tissue lymphoma of the stomach Gastroenterology 117 1999 82 88
29. C.G. Genzor, A. Beldarrain, C. Gomez-Moreno, J.L. Lopez-Lacomba, M. Cortijo, and J. Sancho Conformational stability of apoflavodoxin Protein Sci. 5 1996 1376 1388
30. S. Maldonado, A. Lostao, M.P. Irun, J. Fernandez-Recio, C.G. Genzor, E.B. Gonzalez, J.A. Rubio, A. Luquita, F. Daoudi, and J. Sancho Apoflavodoxin: structure, stability, and FMN binding Biochimie 80 1998 813 820
31. A. Lostao, C. Gomez-Moreno, S.G. Mayhew, and J. Sancho Differential stabilization of the three FMN redox forms by tyrosine 94 and tryptophan 57 in flavodoxin from Anabaena and its influence on the redox potentials Biochemistry 36 1997 14334 14344
32. A. Lostao, M. El Harrous, F. Daoudi, A. Romero, A. Parody-Morreale, and J. Sancho Dissecting the energetics of the apoflavodoxin-FMN complex J. Biol. Chem. 275 2000 9518 9526
33. J. Fernandez-Recio, C.G. Genzor, and J. Sancho Apoflavodoxin folding mechanism: an alpha/beta protein with an essentially off-pathway intermediate Biochemistry 40 2001 15234 15245
34. C.G. Genzor, A. Perales-Alcon, J. Sancho, and A. Romero Closure of a tyrosine/tryptophan aromatic gate leads to a compact fold in apo flavodoxin Nat. Struct. Biol. 3 1996 329 332
35. + reductase. Role of Trp(57) and Tyr(94) J. Biol. Chem. 277 2002 22338 22344
36. M.L. Ludwig, K.A. Pattridge, A.L. Metzger, M.M. Dixon, M. Eren, Y. Feng, and R.P. Swenson Control of oxidation-reduction potentials in flavodoxin from Clostridium beijerinckii: the role of conformation changes Biochemistry 36 1997 1259 1280
37. S.G. Mayhew, and M.L. Ludwig Flavodoxins and electron transferring flavoproteins 1975 Academic Press New York
38. F.C. Chang, and R.P. Swenson Regulation of oxidation-reduction potentials through redox-linked ionization in the Y98H mutant of the Desulfovibrio vulgaris [Hildenborough] flavodoxin: direct proton nuclear magnetic resonance spectroscopic evidence for the redox-dependent shift in the pKa of Histidine-98 Biochemistry 36 1997 9013 9021
39. D.H. Kwon, M.S. Osato, D.Y. Graham, and F.A. El-Zaatari Quantitative RT-PCR analysis of multiple genes encoding putative metronidazole nitroreductases from Helicobacter pylori Int. J. Antimicrob. Agents 15 2000 31 36
40. S.G. Mayhew, and V. Massey Purification and characterization of flavodoxin from Peptostreptococcus elsdenii J. Biol. Chem. 244 1969 794 802
41. J.F. Brandts, and L.N. Lin Study of strong to ultratight protein interactions using differential scanning calorimetry Biochemistry 29 1990 6927 6940
42. M.W. Pantoliano, E.C. Petrella, J.D. Kwasnoski, V.S. Lobanov, J. Myslik, E. Graf, T. Carver, E. Asel, B.A. Springer, P. Lane, and F.R. Salemme High-density miniaturized thermal shift assays as a general strategy for drug discovery J. Biomol. Screen. 6 2001 429 440
43. T.T. Waldron, and K.P. Murphy Stabilization of proteins by ligand binding: application to drug screening and determination of unfolding energetics Biochemistry 42 2003 5058 5064
44. J. Fernandez-Recio, A. Romero, and J. Sancho Energetics of a hydrogen bond (charged and neutral) and of a cation/pi interaction in apoflavodoxin J. Mol. Biol. 290 1999 319 331
45. I. Luque, and E. Freire Structural parameterization of the binding enthalpy of small ligands Proteins 49 2002 181 190
46. M.J. Todd, and E. Freire The effect of inhibitor binding on the structural stability and cooperativity of the HIV-1 protease Proteins 36 1999 147 156
47. T. Wiseman, S. Williston, J.F. Brandts, and L.N. Lin Rapid measurement of binding constants and heats of binding using a new titration calorimeter Anal. Biochem. 179 1989 131 137
48. A.E. Eriksson, W.A. Baase, J.A. Wozniak, and B.M.B.W. Matthews A cavity-containing mutant of T4 lysozyme is stabilized by buried benzene Nature 355 1992 371 373
49. M. Kidd, A.J. Lastovica, J.C. Atherton, and J.A. Louw Heterogeneity in the Helicobacter pylori vacA and cagA genes Gut 45 1999 499 502
50. S.J. Spechler, L. Fischbach, and M. Feldman Clinical aspects of the genetic variability in Helicobacter pylori JAMA 283 2000 1264 1266
51. H. Rautelin, K. Seppala, O.V. Renkonen, U. Vainio, and T.U. Kosunen Role of metronidazole resistance in therapy of Helicobacter pylori infections Antimicrob. Agents Chemother. 36 1992 163 166
52. D.I. Edwards Nitroimidazole drugs-action and resistance mechanisms: I. Mechanisms of action J. Antimicrob. Chemother. 31 1993 9 20
53. D.I. Edwards Nitroimidazole drugs-action and resistance mechanisms: II. Mechanisms of resistance J. Antimicrob. Chemother. 31 1993 201 210